Avant Immunotherapeutics Inc - Current report filing (8-K)
02 Juni 2008 - 10:56PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported):
June 2, 2008
AVANT
IMMUNOTHERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
0-15006
|
|
13-3191702
|
(State or other
jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
119 Fourth Avenue
Needham,
Massachusetts 02494-2725
(Address of
principal executive offices) (Zip Code)
(781) 433-0771
(Registrants
telephone number, including area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01. Other Events
On
June 2, 2008, Pfizer, Inc. and the Registrant issued a press release
concerning certain data with respect to Phase 2 ACTIVATE and ACT II studies
with respect to its CDX-110 product, a copy of which is attached hereto as
Exhibit 99.1
.
The
press release referred to above contains forward-looking information about a
product candidate, CDX-110, including its potential benefits, that involves
substantial risks and uncertainties. Such risks and uncertainties include,
among other things, the uncertainties inherent in research and development;
decisions by regulatory authorities regarding whether and when to approve any
drug applications that may be filed for such product candidate as well as their
decisions regarding labeling and other matters that could affect its
availability or commercial potential; and competitive developments. Other factors that might cause actual results
to differ materially from those in the forward-looking statements including
those set forth under the headings Business, Risk Factors and Managements
Discussion and Analysis of Financial Condition and Results of Operations in
each of the Registrants Annual Report on Form 10-K, its current Reports
on Form 8-K, as well as those described in its other press releases and
filings with the Securities and Exchange Commission, from time to time. You should carefully review all of these
factors, and you should be aware that there may be other factors that could
cause these differences. The
forward-looking statements were based on information, plans and estimates at
the date of the press release, and the Registrant does not promise to update
any forward-looking statements to reflect changes in underlying assumptions or
factors, new information, future events or other changes
Item
9.01. Financial Statements
and Exhibits
Exhibit
|
|
Description
|
99.1
|
|
Press
Release issued June 2, 2008.
|
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
AVANT
IMMUNOTHERAPEUTICS, INC.
|
|
|
|
|
Date:
June 2, 2008
|
By:
|
/s/
Avery W. Catlin
|
|
|
Avery
W. Catlin
|
|
|
Title:
Senior Vice President and
|
|
|
Chief
Financial Officer
|
3
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024